Header Logo

Connection

Kyle Amber to Immunologic Factors

This is a "connection" page, showing publications Kyle Amber has written about Immunologic Factors.
Connection Strength

0.640
  1. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.
    View in: PubMed
    Score: 0.194
  2. Pemphigus subtype: a confounder in determining the association of oral involvement with post-rituximab relapses. Dermatol Ther. 2019 05; 32(3):e12918.
    View in: PubMed
    Score: 0.159
  3. Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center. J Am Acad Dermatol. 2018 04; 78(4):806-808.
    View in: PubMed
    Score: 0.144
  4. Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers. JAMA Dermatol. 2017 11 01; 153(11):1189-1190.
    View in: PubMed
    Score: 0.143
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.